Implication of steady state concentrations of nitrite and nitrate metabolites of nitric oxide in plasma and whole blood in healthy human subjects

2004 ◽  
Vol 31 (9) ◽  
pp. 591-596 ◽  
Author(s):  
Mariko Himeno ◽  
Takaharu Ishibashi ◽  
Shigeru Nakano ◽  
Keisuke Furuya ◽  
Junko Yoshida ◽  
...  
Biorheology ◽  
1987 ◽  
Vol 24 (6) ◽  
pp. 795-801 ◽  
Author(s):  
C.R. Huang ◽  
W.D. Pan ◽  
H.Q. Chen ◽  
A.L. Copley

2000 ◽  
Vol 32 (4) ◽  
pp. 355-362 ◽  
Author(s):  
Timothy England ◽  
Emily Beatty ◽  
Almas Rehman ◽  
Jaffar Nourooz-Zadeh ◽  
Paulo Pereira ◽  
...  

2010 ◽  
Vol 49 (7) ◽  
pp. 449-454 ◽  
Author(s):  
Charles la Porte ◽  
Nha Voduc ◽  
Guijun Zhang ◽  
Isabelle Seguin ◽  
Danielle Tardiff ◽  
...  

2015 ◽  
Vol 35 (suppl_1) ◽  
Author(s):  
Matthijs Moerland ◽  
Karen Malone ◽  
Marlous Dillingh ◽  
Wieke Grievink ◽  
Joannes Reijers ◽  
...  

The role of TNFα in the pathogenesis of atherosclerosis is incompletely understood. TNFα blockade reduces the severity of various autoimmune diseases and the often related atherosclerosis. However, excessively released TNFα is only one component of the hyperactive innate immune system in such diseases. To provide more insight into the role of TNFα in the induction of inflammation, we explored the effects of TNFα blockade in human whole blood. TLR4/NLPR3 inflammasome challenges were applied to induce an inflammatory response. For this purpose, whole blood was incubated 4 hours with LPS and aluminium hydroxide (Alhydrogel). TNFα blockade was evaluated in vitro (LPS/Alhydrogel challenge in whole blood of 4 healthy human subjects, +concentration range of adalimumab) and ex vivo (LPS/Alhydrogel challenge in whole blood of 13 healthy human subjects receiving a single subcutaneous (sc) dose of 40 mg adalimumab). Cytokine release was evaluated in culture supernatants. In vitro, TNFα blockade strongly reduced TNFα levels detected; -97±1% at the lowest adalimumab concentration (0.3125 μg/mL). TNFα blockade did not affect LPS/Alhydrogel-induced IL-6, IL-1β and IL-18 release, but reduced IFNγ release; maximally -93±4% at 5 μg/mL adalimumab. A single sc adalimumab dose in healthy subjects reduced LPS/Alhydrogel-induced TNFα levels (maximally -98±1% on day 4, and still -58±59% on day 64; versus baseline). IL-6, IL-1β and IL-8 release were not reduced after anti-TNFα treatment. The effect of TNFα blockade on IFNγ release could not be reliably estimated due to highly variable IFNγ levels, especially between genders (baseline IFNγ levels 1248±1771 and 140±283 pg/mL, males vs females). TNFα is a major inducer of NFκB-driven cytokine gene transcription, but TNFα blocking did not reduce LPS/Alhydrogel-induced release of IL-1β, IL-6, IL-8 or IL-18 by primary human cells. This suggests that primary TLR4- and inflammasome-mediated signalling is sufficient to drive secretion of these cytokines. However, in vitro TNFα blockade did impair IFNγ release. Since IFNγ is a key factor in atherogenesis, exerting both pro- and anti-atherogenic properties, our data warrant further mechanistic investigation of the role of TNFα and anti-TNFα therapies in atherosclerosis.


2004 ◽  
Vol 286 (6) ◽  
pp. H2468-H2473 ◽  
Author(s):  
Ahmed Tawakol ◽  
Torbjørn Omland ◽  
Mark A. Creager

Epidemiological studies indicate that moderate ethanol consumption reduces cardiovascular mortality. Cellular and animal data suggest that ethanol confers beneficial effects on the vascular endothelium and increases the bioavailability of nitric oxide. The purpose of this study was to assess the effect of ethanol on endothelium-dependent, nitric oxide-mediated vasodilation in healthy human subjects. Forearm blood flow (FBF) was determined by venous occlusion plethysmography in healthy human subjects during intra-arterial infusions of either methacholine (0.3, 1.0, 3.0, and 10.0 mcg/min, n = 9), nitroprusside (0.3, 1.0, 3.0, and 10.0 mcg/min, n = 9), or verapamil (10, 30, 100, and 300 mcg/min, n = 8) before and during the concomitant intra-arterial infusions of ethanol (10% ethanol in 5% dextrose). Additionally, a time control experiment was conducted, during which the methacholine dose-response curve was measured twice during vehicle infusions ( n = 5). During ethanol infusion, mean forearm and systemic alcohol levels were 227 ± 30 and 6 ± 0 mg/dl, respectively. Ethanol infusion alone reduced FBF (2.5 ± 0.1 to 1.9 ± 0.1 ml·dl−1·min−1, P < 0.05). Despite initial vasoconstriction, ethanol augmented the FBF dose-response curves to methacholine, nitroprusside, and verapamil ( P < 0.01 by ANOVA for each). To determine whether this augmented FBF response was related to shear-stress-induced release of nitric oxide, FBF was measured during the coinfusion of ethanol and NG-nitro-l-arginine (l-NAME; n = 8) at rest and during verapamil-induced vasodilation. The addition of l-NAME did not block the ability of ethanol to augment verapamil-induced vasodilation. Ethanol has complex direct vascular effects, which include basal vasoconstriction as well as potentiation of both endothelium-dependent and -independent vasodilation. None of these effects appear to be mediated by an increase in nitric oxide bioavailability, thus disputing findings from preclinical models.


BMC Genomics ◽  
2012 ◽  
Vol 13 (1) ◽  
pp. 636 ◽  
Author(s):  
Kristel R van Eijk ◽  
Simone de Jong ◽  
Marco PM Boks ◽  
Terry Langeveld ◽  
Fabrice Colas ◽  
...  

2007 ◽  
Vol 5 (6) ◽  
pp. 1195-1200 ◽  
Author(s):  
M. U. Zafar ◽  
G. VILAHUR ◽  
B. G. CHOI ◽  
B. IBANEZ ◽  
J. F. VILES-GONZALEZ ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document